Search results
Showing 3201 to 3250 of 3807 results for treatment
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
accelerating access to innovative migraine treatments In this episode, we discuss two innovative migraine treatments...
This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis (HTG67)
Evidence-based recommendations on artificial trapeziometacarpal joint replacement for treating end-stage osteoarthritis. This involves replacing the arthritic joint at the base of the thumb with an artificial joint.
View recommendations for HTG67Show all sections
Sections for HTG67
In development Reference number: GID-TA11406 Expected publication date: TBC
to specialist advice, for example about particular aspects of care and treatment of the person they care for, because this might...
Evidence-based recommendations on percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. This involves inserting a tube called a stent into or across the cystic duct. The aim is to allow bile to flow through the tube, bypassing the blockage and preventing further obstruction.
View recommendations for HTG617Show all sections
history of severe reactions to non-selective NSAIDs may enable them to have treatment with an anti-inflammatory without specialist drug...
Evidence-based recommendations on mini-incision surgery for total knee replacement. This involves using specially designed instruments to replace the knee using a smaller incision.
View recommendations for HTG220Show all sections
Sections for HTG220
In development Reference number: GID-TA11301 Expected publication date: TBC
In development Reference number: GID-TA11800 Expected publication date: TBC
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
The PediGuard for placing pedicle screws in spinal surgery (MIB26)
NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery
recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...
Swallowable gastric balloon capsule for weight loss (HTG561)
Evidence-based recommendations on swallowable gastric balloon capsules for weight loss in adults. This involves swallowing a capsule containing a balloon that is then filled with liquid to inflate it in the stomach.
View recommendations for HTG561Show all sections
describe details of patient selection, particularly in relation to previous treatments. They should also describe clinical outcomes...
recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...
recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...
Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.
In development Reference number: GID-TA11500 Expected publication date: TBC
NaviCam for diagnosing gastrointestinal tract conditions (MIB104)
NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .
Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.
View recommendations for HTG699Show all sections
NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
NICE has withdrawn this guidance. Sobi will stop marketing inotersen (Tegsedi) because its no longer available in the UK. Healthcare professionals should discuss alternative treatment options with people currently having inotersen.
Our science policy and research programme team produces high-quality, impactful research.
We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)
Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.
View recommendations for HTG560Show all sections
Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.
View recommendations for HTG173Show all sections
Sections for HTG173
Evidence-based recommendations on implant insertion for prominent ears in children, young people and adults. This involves inserting small curved implants under the skin of each ear.
View recommendations for HTG526Show all sections
NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details
this applies to you, because it may not be safe for you to reduce or stop treatment. Street benzos Street benzos are street drugs which...
Discontinued Reference number: GID-TA11289
Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.
View recommendations for HTG737Show all sections
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
In development Reference number: GID-TA11771 Expected publication date: TBC
Violent and aggressive behaviours in people with mental health problems (QS154)
This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.
View quality statements for QS154Show all sections
Sections for QS154
- Quality statements
- Quality statement 1: Identifying triggers and warning signs
- Quality statement 2: Preventing and managing violent or aggressive behaviour
- Quality statement 3: Physical health during and after manual restraint
- Quality statement 4: Physical health after rapid tranquillisation
- Quality statement 5: Immediate post-incident debrief
- About this quality standard
This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board